Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$25.90 USD
-0.91 (-3.39%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $25.93 +0.03 (0.12%) 7:58 PM ET
5-Strong Sell of 5 5
B Value B Growth B Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PCRX 25.90 -0.91(-3.39%)
Will PCRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PCRX
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
PCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings
Pacira (PCRX) Matches Q4 Earnings Estimates
Acadia Healthcare (ACHC) Q4 Earnings and Revenues Surpass Estimates
Other News for PCRX
Commit To Buy Pacira BioSciences At $17.50, Earn 10.4% Annualized Using Options
Noteworthy Tuesday Option Activity: PCRX, CMG, CVNA
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
Understanding Key Factors Behind Pacira Pharmaceuticals’ Analyst Rating
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)